<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1362</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15380274</PubmedId>
            <Abstract>The surface expression of 9-O-acetylated sialic acid (9-OAcSA) is elevated on hematopoietic cells and erythrocytes of visceral leishmaniasis (VL) patients. In this study, we show that VL patients contain elevated levels of IgM antibodies directed against 9-O-acetylated sialoglycoconjugates (9-OAcSG). These antibodies were affinity purified with bovine submaxillary protein as the affinity matrix containing the terminal epitope, 9-OAcSAalpha2-6GalNAc. They also bound to 9-OAcSGs on hematopoietic cells of patients with VL and to epitopes in the cytosol of Leishmania donovani promastigotes. A novel enzyme-linked immunosorbent assay was employed that showed 4-fold higher anti-OAcSG titers in VL patients (n=38), mean +/- S.E.M. being 0.83 +/- 0.09 vs. 0.21 +/- 0.04 detected in normal donors (n=20) and patients with cross-reactive diseases such as malaria (n=4) or tuberculosis (n=4). Assay specificity and sensitivity was 100% and 92%, respectively, whereas positive and negative predictive values were 100% and 90%, respectively. Significantly, anti-OAcSG titers declined 30 days after completion of anti-leishmanial treatment, indicating that monitoring of anti-9-OAcSGs may be a valuable alternative toward increasing the efficiency of diagnosis and follow-up of VL.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>15-24</ArticlePages>
            <ArticleTitle>Purification, characterization of O-acetylated sialoglycoconjugates-specific IgM, and development of an enzyme-linked immunosorbent assay for diagnosis and follow-up of indian visceral leishmaniasis patients.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bandyopadhyay</LastName>
                    <ForeName>Sumi</ForeName>
                </Author>
                <Author>
                    <LastName>Chatterjee</LastName>
                    <ForeName>Mitali</ForeName>
                </Author>
                <Author>
                    <LastName>Pal</LastName>
                    <ForeName>Santanu</ForeName>
                </Author>
                <Author>
                    <LastName>Waller</LastName>
                    <ForeName>Ross F</ForeName>
                </Author>
                <Author>
                    <LastName>Sundar</LastName>
                    <ForeName>Shyam</ForeName>
                </Author>
                <Author>
                    <LastName>McConville</LastName>
                    <ForeName>Malcolm J</ForeName>
                </Author>
                <Author>
                    <LastName>Mandal</LastName>
                    <ForeName>Chitra</ForeName>
                </Author>
            </Authors>
            <Affiliations>Immunobiology Division, Indian Institute of Chemical Biology, Jadavpur, Kolkata, India.</Affiliations>
            <ArticleChemicalList>Antibodies, Anti-Idiotypic;Glycoconjugates;Immunoglobulin M;Sialic Acids</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acetylation; Animals; Antibodies, Anti-Idiotypic(analysis); Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Glycoconjugates(analysis); Humans; Immunoglobulin M(analysis); India(epidemiology); Leishmania donovani(immunology); Leishmaniasis, Visceral(diagnosis; epidemiology; immunology); Male; Risk Assessment; Sensitivity and Specificity; Sialic Acids(analysis; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>50</Volume>
                <Issue>1</Issue>
                <Title>Diagnostic microbiology and infectious disease</Title>
                <Issn>0732-8893</Issn>
                <MedlineTa>Diagn Microbiol Infect Dis</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>9-O-AcSA-Î±(2-6)GalNAc</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalNonSequenceMolecule>
                        <ChemicalType>Carbohydrate fragment</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:59571</ChEBIId>
                        </Molecule>
                        <SourceMolecule>
                            <GenBankId>P98091.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9913</SourceOrganismId>
                    </FragmentOfANaturalNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors communication</LocationOfData>
                <EpitopeId>140429</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The 9O-acetyalted sialic acid (SA) sugar is also known as Neu5,9Ac2 and stands for N-acetyl-9-0-acetylneuraminic acid. This epitope is a disaccharide, that is typically found as the terminal part of the N-glycan in sialidated glycproteins.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <BCellId>24218</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Environmental exposure to endemic/ubiquitous agent without evidence for disease</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5658</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Sera was obtained from healthy individuals from endemic areas for Leishmania.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Epitope-containing bovine submaxillary protein is not recognized by sera from healthy individuals from endemic leishmaniasis areas, which also fail to recognize leishmania in anti-parasite ELISA. This epitope is found in high levels in infected individuals' PBMCs and erythrocytes, and the reactivity against this epitope is seen to correlate with the amount of epitope expressed in those cell types from patients or healthy donors. Similar results are obtained with healthy individuals form non-endemic areas (n=10) and for patients of malaria (n=4) or tuberculosis (n=4).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P98091.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9913</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <BCellId>24217</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:9146</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5658</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Leishmaniasis patients' sera were assayed at the moment of active infection and following completion of treatment.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>38</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>35</NumberOfSubjectsResponded>
                            <ResponseFrequency>92.1</ResponseFrequency>
                            <AssayComments>Epitope-containing bovine submaxillary protein is recognized by leishmaniasis patients sera in a similar fashion than the parasite in anti-parasite ELISA. These reactivities are highly reduced upon completion of anti-leishmaniasis treatment. This epitope is found in high levels in infected individuals' PBMCs and erythrocytes, and the reactivity against this epitope is seen to correlate with the amount of epitope expressed in those cell types from patients or normal donors.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P98091.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9913</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>24221</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:9146</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5658</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Leishmania</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Anti-epitope IgM were purified from patients sera by affinity chromatography.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Parasites (L. donovani MHOM/IN/83/AG83) are recognized by anti-epitope purified IgM (from a pool of Leishmania patients sera), and specific fluorescence is seen throughout the cytoplasm. This binding is inhibited by competition with anti-epitope lectin Achatinin-H, demonstrating its specificity towards the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal-Monospecific</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>5661</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3 B and D</LocationOfData>
                        <BCellId>24219</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:9146</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5658</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Anti-epitope IgM were purified from patients sera.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>PBMCs and erythrocytes from patients are specifically recognized by anti-epitope purified IgM (from a pool of Leishmania patients sera), while minimal binding is obtained against normal donors' cells.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal-Monospecific</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

